Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $2.00 target price on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Trading Down 5.0 %

Senseonics stock opened at $0.34 on Tuesday. Senseonics has a 12-month low of $0.32 and a 12-month high of $0.75. The company has a debt-to-equity ratio of 59.17, a current ratio of 3.11 and a quick ratio of 2.89. The stock has a market capitalization of $182.62 million, a PE ratio of -2.46 and a beta of 0.79. The firm has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.42.

Senseonics (NYSE:SENS) last released its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The firm had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. As a group, equities research analysts expect that Senseonics will post -0.13 EPS for the current fiscal year.

Institutional Trading of Senseonics

Large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after acquiring an additional 211,128 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in shares of Senseonics in the 1st quarter worth $91,000. Vanguard Group Inc. raised its position in shares of Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Senseonics in the 1st quarter valued at $162,000. 12.36% of the stock is currently owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.